

Ministry of Health

Drugs and Devices Division

Drug Submission Status

Report for March 2020

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Jamp Pharma Corporation	Jamp Zolmitriptan	Zomig	Zolmitriptan	2.5mg	tablet	02477106
Jamp Pharma Corporation	Jamp-Febuxostat	Uloric	febuxostat	80mg	tablet	02490870
Fresenius Kabi Canada Ltd.	Caspofungin For Injection	Candidas	caspofungin acetate	50mg/vial	powder for injection	02486989
Fresenius Kabi Canada Ltd.	Caspofungin For Injection	Candidas	caspofungin acetate	70mg/vial	powder for injection	02486997
Natco Pharma (Canada) Inc.	Nat-Cetirizine	Reactine	cetirizine HCl	10mg	tablet	02496461
Natco Pharma (Canada) Inc.	Nat-Cetirizine	Reactine	cetirizine HCl	20mg	tablet	02496488

Auro Pharma Inc.	Auro-Progesterone	Prometrium	Progesterone	100 mg	capsule	02493578
Taro Pharmaceuticals Inc.	Taro-Bosentan	Tracleer	bosentan (as bosentan monohydrate)	62.5 mg	tablet	02483130
Taro Pharmaceuticals Inc.	Taro-Bosentan	Tracleer	bosentan (as bosentan monohydrate)	125mg	tablet	02483149